Introduction
Cardiovascular diseases (CVD) hold a leading place in the world among other nosology's by the number of deaths of the working-age population. In the field of healthcare of the leading countries of the world, the government programs for drug reimbursement are increasingly introduced to improve the availability and quality of medical and pharmaceutical care to all segments of the population [1] [2] [3] . Since 2012, government projects and programs to increase the availability of pharmaceutical care to all segments of the population have been implemented in the healthcare of Ukraine. In 2017, the government program "Available medicines" was introduced with the aim of providing patients with life-saving necessary medicines for the treatment of nosologies, such as CVD, asthma and type II diabetes [3] . In the same year, thanks to the support of Management Sciences for Health (MSH), the project "Safe, available and effective medicines for Ukrainians" (SAFEMed) began its work in Ukraine. Its main goal is to improve the financing mechanisms of the national healthcare system [4] .
As practice has shown, the pharmacotherapy of CVD is quite expensive and long due to the peculiarity of the disease course and the presence of concomitant nosologies in a patient. Therefore, the rational use of budgetary funds is one of the main components for further development of the healthcare system.
Aim of the research
The aim of our study was to develop a method for predicting the indicators for drug reimbursement to patients with CVD in Ukraine within the framework of the government program "Available medicines".
3.Materials and methods
Materials from the official Express issues formed by the State Statistics Service of Ukraine (within 2013-2018); medical records of patients with CVD, who were prescribed medicines according to the government program for reimbursement; the data of our preliminary pharmacoeconomical analysis of treatment regimens of patients with CVD were used in the study [5] [6] [7] . Statistical, analytical, mathematical methods and the method of generalization of scientific information were applied in the work. The method of the study is presented in Fig. 1 .
Fig. 1. The research method for predicting the indicators for drug reimbursement to patients with cardiovascular diseases
Despite the fact that CVD have a significant variation in morbidity indicators their ranking by regions of Ukraine was conducted according to three groups ( Table 1) . 3 
ІV stage
Formulation and discussion of the conclusions of the study ІІІ stage Forecast of the indicators for reimbursement of drug cost to patients with CVD by the government program ІІ stage Forecasting the number of patients with CVD in the territory administration units of the country and the country as a whole І stage Formation of a sample of drugs on the basis of marketing, clinical and economic studies The first group contained regions with low morbidity, for which fluctuations in the incidence were within 1965-3622 cases; in the second group there were regions with an average incidence of 3623-5280 cases, and the third group comprised regions of Ukraine with a high incidence of CVD, which incidence rate ranged from 5281 to 6938 cases per 100 thousand population. In total, the first and second group included 20 regions, which was 86.95 % of the total number of territory administration units. In the third group there were three regions with the share of 13.05 %. It should be noted that they are industrial-agricultural and port regions of Ukraine, their highest incidence rate is characterized by inadequate indicators of quality of life.
For calculations, the program STATISTICA was used for each region of the country, and the regression loglinear model and the determination coefficient were calculated. Prognosis of indicators of prevalence of patients with CVD in territory administration units of the country was done for 2019-2020 (per 100 thousand of the population).
Result
The low level of state funding, inefficient allocation of budget funds between regions of the country and their spending are the main problems of development of the healthcare system of Ukraine [8] . As a result, patients have to pay most of the money for the treatment from their family budget. In this regard, the solution of these problems is a priority in further development and reforming of the national healthcare in Ukraine. [9] . Thus, the proper access of all segments of the population to timely, high-quality and affordable medical and pharmaceutical care is possible only with reasonable calculations of indicators of drug reimbursement, in particular under the government programs [10] .
According to the method proposed for forecasting the volume of drug reimbursement to patients with CVD under the government program it has been found that Сlopidogrel has the highest indicator -12108.13 USD thousand in 2019 and 11908.24 USD thousand in 2020 ( Table 2) .
Enalapril takes the second position -10916.39 USD thousand and 10736.18 USD thousand, while Amlodipine occupies the third position -9105.60 USD thousand and 8955281.42 USD thousand. Among the medicines not included in the government program, but prescribed rather frequently the largest forecasting amount required for reimbursement (in case of inclusion in the program) is 18910.55 USD thousand in 2019 and 18598.36 USD thousand in 2020 for Magnicor, and the least amount is 444.55 USD thousand and 437.22 USD thousand for Acetylsalicylic acid, respectively. At the next stage, drug reimbursement for patients with CVD in the regions of the country for 2019 and 2020 was calculated ( Table 3 ). The regions of the country were located according to the ranking, which is shown in Table 1 .
Thus, for 2019 and 2020, the highest indicators among medicines recommended for inclusion in the program under condition of its expansion are observed in the Mykolaivska region for Magnicor, should be noted that there is a relationship between the results of ranking the regions of Ukraine by the incidence of CVD and the volume of the forecasting amount of compensation. Thus, the highest forecasting amount of compensation was determined in the Mykolaivska region, which was referred in the process of ranking to the third group of regions with a high incidence of the population, and the smallest figures of the estimated amounts of compensation were observed in the Khersonska region referred to the first group -regions with low morbidity of the population. The overall average indicators of drug reimbursement in Ukraine are 67605.8 USD thousand for 2019, and 65604.2 USD thousand for 2020. The overall average indicator of forecasting drug reimbursement in the regions of the country per one patient was also calculated and ranked in three groups (Tables 4, 5) .
In particular, for 2019 the first group contained such medicines as Acetylsalicylic acid, Hy- The second group contained such medicines as Amlodipine, Clopidogrel, Enalapril in all regions except those referred to the first group and Magnicor by the indicator in the Vinnytska region. Thus, Magnicor was in the third group as in 2019. Therefore, in 2019 and 2020 Acetylsalicylic acid, in case of its inclusion in the program, has the lowest forecasting overall average indicator of drug reimbursement in the Khersonska region -1.89 and 1.36 USD per one patient. In case of inclusion of the drug in the program In case of its inclusion in the program Magnicor has also the highest indicator -225.36 USD per one patient in 2019 and 210.99 USD in 2020. Table 3 Original Research Article: full paper (2019), «EUREKA: Health Sciences» Number 4 In particular, both in 2019 and in 2020 the lowest indicator of consumption of all drugs studied is in the Khersonska region, and the highest indicator is in the Mykolaivska region. There is also an uneven consumption of medicines involved in the program among the regions of Ukraine. This is due to the fact that the uneven number of pharmacies participating in the program by regions of the country is involved.
Continuation of
Taking into account the further prospect of expanding the government program it should be noted that Acetylsalicylic acid is an affordable, effective and safe antiplatelet agent in the treatment of CVD and is included in the list of essential drugs recommended by the WHO in the doses of Pharmacology, Toxicology and Pharmaceutical Science 500 and 100 mg. Therefore, its inclusion in the list of the drugs reimbursed is an effective step towards improving pharmaceutical care for patients with CVD. For 2019 the forecasting amount of drug reimbursement for Clopidogrel is 12108.13 USD thousand, and for Acetylsalicylic acid (in case of its inclusion in the program) it is 444.55 USD thousand, therefore, it is 11663,57 USD thousand (by 27.24 %) less. For example, if a physician prescribes medicines containing acetylsalicylic acid to patients (if the medicine is well tolerated), instead of Clopidogrel, the state will be able to distribute and save budget funds more rationally [11, 12] . 
